Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FZL03
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,357
Award facts
- Contract value 100% obligated
- $11,357.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $11,357.40 by the Defense Logistics Agency on September 3, 2025, for the supply of Nucala 100 mg/ml auto-injectors. The delivery order carries an ultimate completion date of September 4, 2025, and does not utilize a set-aside designation. This award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499,999,999 single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies for Department of Defense healthcare facilities.
The DLA, which operates as the federal government's centralized wholesale and retail supply chain management organization for the military, regularly issues delivery orders against this IDC to fulfill ongoing pharmaceutical needs at military health facilities nationwide. Nucala (mepolizumab) is a biologic medication used in the treatment of severe eosinophilic asthma and other eosinophilic conditions, and the auto-injector formulation provides a convenient administration method for patients requiring this specialty pharmaceutical. As a established federal contractor with consistent performance across multiple pharmaceutical product categories, DMS Pharmaceutical Group maintains critical supplier status within the Defense Logistics Agency's pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DB25FZL03?
SPE2DB25FZL03 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FZL03 worth?
The government has obligated $11,357 on SPE2DB25FZL03.
Is contract SPE2DB25FZL03 an order under another contract?
Yes. SPE2DB25FZL03 is a delivery order under SPE2DB20D9329, an indefinite delivery contract.
Was contract SPE2DB25FZL03 competed?
The extent of competition for SPE2DB25FZL03 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award